Chronic Drooling - Pipeline Review, H2 2011

Chronic Drooling - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Chronic Drooling - Pipeline Review, H2 2011', provides an overview of the Chronic Drooling therapeutic pipeline. This report provides information on the therapeutic development for Chronic Drooling, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Drooling. 'Chronic Drooling - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chronic Drooling.
- A review of the Chronic Drooling products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Drooling pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chronic Drooling.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Drooling pipeline depth and focus of Chronic Drooling therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Chronic Drooling Therapeutic Products under Development, Key Players in Chronic Drooling Therapeutics, Chronic Drooling Pipeline Overview, Chronic Drooling Pipeline, Chronic Drooling Pipeline Assessment SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Drooling Overview
Therapeutics Development
An Overview of Pipeline Products for Chronic Drooling
Chronic Drooling Therapeutics under Development by Companies
Chronic Drooling Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Chronic Drooling Therapeutics - Products under Development by Companies
Chronic Drooling Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Chronic Drooling Therapeutics Development
ORIENT PHARMA CO., LTD.
NeuroHealing Pharmaceuticals Inc.
Chronic Drooling - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
SMT D001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NH004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amisulpride + Moclobemide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chronic Drooling Therapeutics – Drug Profile Updates
Chronic Drooling - Featured News
Aug 26, 2011: The Michael J Fox Foundation Grants Second Award To NeuroHealing For Clinical Trial Of NH004 For Sialorrhea Control In Parkinson’s Disease
Dec 10, 2010: NeuroHealing Reports Positive Results From Phase II Study Of NH004 For Treatment Of Sialorrhea
Jun 09, 2009: Interim Results Of Phase II Trial For The Treatment Of Sialorrhea To Be Presented At Movement Disorder Society International Congress June 11th
Sep 24, 2008: NeuroHealing Pharmaceuticals To Present At Drug Repositioning Summit
Feb 19, 2008: NeuroHealing Pharmaceuticals Initiates Phase II Clinical Trial of NH004 for Sialorrhea Control in Parkinson’s Disease Patients
Jan 16, 2008: Summit Plc’s Lead Drug Candidate, SMT D001, Enters Phase II Clinical Trials
Dec 13, 2007: The Michael J. Fox Foundation Awards Funding To NeuroHealing Pharmaceuticals Researchers For A Phase II Clinical Trial Of NH004 For Sialorrhea Control In Parkinson’s Disease Patients
Apr 06, 2006: Biotech angel invests $US500,000 in CNS company
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Chronic Drooling, H2 2011
Products under Development for Chronic Drooling – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
ORIENT PHARMA CO., LTD., H2 2011
NeuroHealing Pharmaceuticals Inc., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Chronic Drooling Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Chronic Drooling, H2 2011
Products under Development for Chronic Drooling – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011